Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits